28 Jun 2019
Posted in Pharma
Dupixent boost from FDA approval will see drug achieve blockbuster status in 2019 and estimated sales of $6.4bn in 2025
Following the news that the FDA has approved Dupixent for the treatment of chronic rhinosinusitis with nasal polyposis, Philippa Salter, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view:
“Dupixent is the first biologic to be approved for the treatment of chronic rhinosinusitis with nasal polyposis, beating rivals in gaining market approval and first-to-market advantage.
“GlobalData is forecasting that this momentum will see Dupixent reach blockbuster status with $1.9bn in revenue in 2019 with further revenue growth to $6.4bn by 2025.
“Sanofi is building on the success of Dupixent with its approval in a third indication in as many years set to boost sales further after it was approved for atopic dermatitis in 2017 and moderate-to-severe asthma in 2018.”